Treatment of metastatic breast cancer: Looking towards the future

Surabhi Amar, Vivek Roy, Edith A. Perez

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The armamentarium for the treatment of metastatic breast cancer is increasing with the introduction of newer chemotherapeutic agents and the development of molecular targeted therapies. The clinical utility of anthracyclines in advanced breast cancer has been limited by significant adverse events; therefore the taxanes are increasingly used in the metastatic setting. Trastuzumab with a taxane as first-line therapy is now standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Other targeted therapies, including the antiangiogenesis agents such as bevacizumab, are being investigated both as monotherapy and in combination regimens. While the number of available agents is growing rapidly, challenges remain concerning appropriate dose, schedule, treatment duration and management of drug resistance. This paper reviews recent data regarding the established and investigational medical treatments for endocrine-refractory metastatic breast cancer, and presents treatment recommendations.

Original languageEnglish (US)
Pages (from-to)413-422
Number of pages10
JournalBreast Cancer Research and Treatment
Volume114
Issue number3
DOIs
StatePublished - Apr 2009

Fingerprint

Breast Neoplasms
Molecular Targeted Therapy
Therapeutics
Taxoids
Investigational Therapies
Anthracyclines
Standard of Care
Drug Resistance
Appointments and Schedules

Keywords

  • Bevacizumab
  • Docetaxel
  • Lapatinib
  • Metastatic breast cancer
  • Paclitaxel
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of metastatic breast cancer : Looking towards the future. / Amar, Surabhi; Roy, Vivek; Perez, Edith A.

In: Breast Cancer Research and Treatment, Vol. 114, No. 3, 04.2009, p. 413-422.

Research output: Contribution to journalArticle

Amar, Surabhi ; Roy, Vivek ; Perez, Edith A. / Treatment of metastatic breast cancer : Looking towards the future. In: Breast Cancer Research and Treatment. 2009 ; Vol. 114, No. 3. pp. 413-422.
@article{1044c418d0d94c0cb592df99cb44c36d,
title = "Treatment of metastatic breast cancer: Looking towards the future",
abstract = "The armamentarium for the treatment of metastatic breast cancer is increasing with the introduction of newer chemotherapeutic agents and the development of molecular targeted therapies. The clinical utility of anthracyclines in advanced breast cancer has been limited by significant adverse events; therefore the taxanes are increasingly used in the metastatic setting. Trastuzumab with a taxane as first-line therapy is now standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Other targeted therapies, including the antiangiogenesis agents such as bevacizumab, are being investigated both as monotherapy and in combination regimens. While the number of available agents is growing rapidly, challenges remain concerning appropriate dose, schedule, treatment duration and management of drug resistance. This paper reviews recent data regarding the established and investigational medical treatments for endocrine-refractory metastatic breast cancer, and presents treatment recommendations.",
keywords = "Bevacizumab, Docetaxel, Lapatinib, Metastatic breast cancer, Paclitaxel, Trastuzumab",
author = "Surabhi Amar and Vivek Roy and Perez, {Edith A.}",
year = "2009",
month = "4",
doi = "10.1007/s10549-008-0032-3",
language = "English (US)",
volume = "114",
pages = "413--422",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Treatment of metastatic breast cancer

T2 - Looking towards the future

AU - Amar, Surabhi

AU - Roy, Vivek

AU - Perez, Edith A.

PY - 2009/4

Y1 - 2009/4

N2 - The armamentarium for the treatment of metastatic breast cancer is increasing with the introduction of newer chemotherapeutic agents and the development of molecular targeted therapies. The clinical utility of anthracyclines in advanced breast cancer has been limited by significant adverse events; therefore the taxanes are increasingly used in the metastatic setting. Trastuzumab with a taxane as first-line therapy is now standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Other targeted therapies, including the antiangiogenesis agents such as bevacizumab, are being investigated both as monotherapy and in combination regimens. While the number of available agents is growing rapidly, challenges remain concerning appropriate dose, schedule, treatment duration and management of drug resistance. This paper reviews recent data regarding the established and investigational medical treatments for endocrine-refractory metastatic breast cancer, and presents treatment recommendations.

AB - The armamentarium for the treatment of metastatic breast cancer is increasing with the introduction of newer chemotherapeutic agents and the development of molecular targeted therapies. The clinical utility of anthracyclines in advanced breast cancer has been limited by significant adverse events; therefore the taxanes are increasingly used in the metastatic setting. Trastuzumab with a taxane as first-line therapy is now standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Other targeted therapies, including the antiangiogenesis agents such as bevacizumab, are being investigated both as monotherapy and in combination regimens. While the number of available agents is growing rapidly, challenges remain concerning appropriate dose, schedule, treatment duration and management of drug resistance. This paper reviews recent data regarding the established and investigational medical treatments for endocrine-refractory metastatic breast cancer, and presents treatment recommendations.

KW - Bevacizumab

KW - Docetaxel

KW - Lapatinib

KW - Metastatic breast cancer

KW - Paclitaxel

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=61449222107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449222107&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-0032-3

DO - 10.1007/s10549-008-0032-3

M3 - Article

C2 - 18465221

AN - SCOPUS:61449222107

VL - 114

SP - 413

EP - 422

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -